Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.
If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.
* Price is subject to applicable taxes.
Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.
(NewsDirect)
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) CEO Steve Saviuk joined Proactive's Stephen Gunnion to discuss the company's strong position on the Globe and Mail's Report on Business annual list of Canada’s top-growing companies.
The company placed 151 out of 425 companies, with a three-year growth rate of 322%.
Saviuk explained that the rankings are calculated on revenue growth, and the exponential growth in the company's Enerzair asthma therapy helped it secure its position. Despite launching less than two years ago, he said Enerzair already ranks second in Canada's inhaled asthma drug market, accounting for approximately one out of every five prescriptions.
Given the current trajectory, Saviuk said the company may rank even higher in 2024.
The Report on Business magazine launched Canada’s Top Growing Companies ranking in 2019 and companies have to complete an in-depth application process and fulfill certain requirements in order to be recognized.
Valeo Pharma is a fast-growing Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology and Hospital Specialty Products.
Proactive
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.